QBECO SSI is a new investigational treatment for inflammatory bowel disease.

Rather than suppressing the immune system like current IBD treatments, QBECO SSI is designed to restore the body’s innate immune system and correct the dysfunctional immune response. Participants are being enrolled in a clinical trial to study QBECO SSI for the treatment of ulcerative colitis.

Clinical trial experience in Crohn’s Disease

Summary of clinical trial results

Clinical trial experience in ulcerative colitis


Summary of clinical trial results

Learn About
QBECO SSI Treatment

QBECO SSI is derived from components of inactivated E. coli.

Qu Biologics Site Specific Immunomodulators

Dr. Hal Gunn talks about Site Specific Immunomodulators (SSIs), investigational new treatments for IBD.  Dr. Gunn talks about Qu Biologics’ research of immune system dysfunction and how SSIs, which are derived from inactivated bacterial components, may stimulate an innate immune response in the GI tract to reverse the underlying chronic bacterial infection/dysbiosis related to IBD.

IBD Clinical Trial Information for Gastroenterologists

Qu Biologics’ CEO, Dr. Hal Gunn, talks about the research behind QBECO SSI and how this investigational treatment is designed to resolve the underlying trigger for Crohn’s disease and ulcerative colitis.